Table III.
Preliminary efficacy results from phase 3 trials and approval status of the 9 frontrunner COVID-19 vaccines
| Manufacturer | Platform No. of doses |
1° Efficacy endpoint (reference in superscript where applicable) | Efficacy % (95% CI) | Approval status |
|---|---|---|---|---|
| Pfizer BNT162b2 |
mRNA 2 doses |
PCR+ symptomatic COVID-19 ≥7 days after dose 27 | 95 (90.3-97.6) | Approved in 113 countries |
| Moderna mRNA-1273 | mRNA 2 doses |
Symptomatic COVID-19 ≥14 days after dose 28 | 94.1 (89.3-96.8) | Approved in 77 countries |
| AstraZeneca ChAdOx1-S |
nrVV 2 doses |
PCR+ symptomatic COVID-19 ≥15 days after dose 29 | 54.9 (32.7-69.7)∗ 82.4 (62.7-91.7)∗ | Approved in 172 countries |
| Janssen Ad26.COV2.S |
nrVV 1 dose |
Moderate or severe COVID-19 ≥14 days after dose 110 | 66.9 (59-73.4) | Approved in 79 countries |
| Gamaleya Sputnik V |
nrVV 2 doses |
PCR+ COVID-19 ≥21 days after dose 111 | 91.6 (85.6-92.2) | Approved in 74 countries |
| CanSino Convidecia |
nrVV 1 dose |
Symptomatic COVID-19 ≥14 days after dose 1 | 65.7†,‡ | Approved in 9 countries |
| Novavax NVX-CoV-2373 |
Protein 2 doses |
PCR+ symptomatic COVID-19 ≥7 days after dose 212 | 89.7 (80.2-94.6) | Not approved |
| Sinopharm BBIBP-CorV |
IV 2 doses |
Symptomatic COVID-19 ≥14 days after dose 213 | 78.1 (64.8-86.3) | Approved in 77 countries |
| Sinovac CoronaVac |
IV 2 doses |
PCR+ symptomatic COVID-19 ≥14 days after dose 214 | 50·7 (36·0-62·0)† | Approved 49 countries |
Ad, Adenovirus; ChAd, chimpanzee adenovirus; IV, inactivated vaccine; nrVV, nonreplicating viral vector; PCR+, SARS-CoV-2 detected on nasopharyngeal swab by polymerase chain reaction.
Only leading COVID-19 vaccine candidates with published phase 3 trial results are listed here. There are 20 vaccines with regulatory approval (most provisional or emergency use only) in at least 1 country but not all have released phase 3 trial results. Approved vaccines not listed in the table include 7 inactivated virus vaccines (Sinopharm Wuhan's WIBP-CorV licensed in 5 countries including China; Minhai Biotechnology's vaccine approved in China; Chinese Academy of Medical Sciences Vaccine approved in China; Bharat Biotech's BBV152 [called Covaxin] approved in 20 countries; Russian Academy of Sciences CoviVac [KoviVac] approved in Russia; Kazakhstan RIBSP's QazCovid-in [called QazVac] approved in Kazakhstan; Shifa Pharmed Industrial Co's COVIran Barakat approved in Iran) and 4 protein-based vaccines (Anhui's ZF2001 [called ZIFIVAX] approved in China and Uzbekistan; Cuba's CIGB-66 [called Abdala] licensed in Cuba and Venezuela; Instituto Finlay de Vacunas' FINLAY-FR-2 [called Soberana 02] approved in Cuba and Iran; and Russia's EpiVacCorona peptide-based vaccine approved in Russia, Belarus, and Turkmenistan). The Novavax protein-based vaccine is a leading candidate but has not yet been granted approval for use in any country.
Efficacy depends on dosing interval with greater efficacy with increasing interval—4-week (above) and 12-week (below) dosing results shown.
Results unpublished and figures based on media reports from trials in various countries.
95% confidence interval not known.